Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) FCF Margin (2024 - 2025)

Kairos Pharma (KAPA) has disclosed FCF Margin for 2 consecutive years, with 1.61% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, FCF Margin fell 140161.0% year-over-year to 1.61%, compared with a TTM value of 5.37% through Jun 2025, changed N/A, and an annual FY2024 reading of 7.91%, up 18495.0% over the prior year.
  • FCF Margin was 1.61% for Q2 2025 at Kairos Pharma, down from 1.43% in the prior quarter.
  • Across five years, FCF Margin topped out at 1400.0% in Q2 2024 and bottomed at 225.0% in Q1 2024.